Imperial College London
Portrait Picture

MrMikaelSodergren

Faculty of Medicine, Department of Surgery & Cancer

Clinical Senior Lecturer in Hepatopancreatobiliary Surgery
 
 
 
//

Contact

 

m.sodergren

 
 
//

Location

 

BN2/13Block B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Rifkin-Zybutz:2023:10.1007/s00213-023-06399-3,
author = {Rifkin-Zybutz, R and Erridge, S and Holvey, C and Coomber, R and Gaffney, J and Lawn, W and Barros, D and Bhoskar, U and Mwimba, G and Praveen, K and Symeon, C and Sachdeva-Mohan, S and Rucker, JJ and Sodergren, MH},
doi = {10.1007/s00213-023-06399-3},
journal = {Psychopharmacology},
pages = {1735--1745},
title = {Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: a cohort study from the UK Medical Cannabis Registry},
url = {http://dx.doi.org/10.1007/s00213-023-06399-3},
volume = {240},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - RationaleCannabis-based medicinal products (CBMPs) have been identified as novel therapeutics for generalised anxiety disorder (GAD) based on pre-clinical models; however, there is a paucity of high-quality evidence on their effectiveness and safety.ObjectivesThis study aimed to evaluate the clinical outcomes of patients with GAD treated with dried flower, oil-based preparations, or a combination of both CBMPs.MethodsA prospective cohort study of patients with GAD (n = 302) enrolled in the UK Medical Cannabis Registry prescribed oil or flower-based CBMPs was performed. Primary outcomes were changes in generalised anxiety disorder-7 (GAD-7) questionnaires at 1, 3, and 6 months compared to baseline. Secondary outcomes were single-item sleep quality scale (SQS) and health-related quality of life index (EQ-5D-5L) questionnaires at the same time points. These changes were assessed by paired t-tests. Adverse events were assessed in line with CTCAE (Common Terminology Criteria for Adverse Events) v4.0.ResultsImprovements in anxiety, sleep quality and quality of life were observed at each time point (p < 0.001). Patients receiving CBMPs had improvements in GAD-7 at all time points (1 month: difference −5.3 (95% CI −4.6 to −6.1), 3 months: difference −5.5 (95% CI −4.7 to −6.4), 6 months: difference −4.5 (95% CI −3.2 to −5.7)). Thirty-nine participants (12.9%) reported 269 adverse events in the follow-up period.ConclusionsPrescription of CBMPs in those with GAD is associated with clinically significant improvements in anxiety with an acceptable safety profile in a real-world setting. Randomised trials are required as a next step to investigate the efficacy of CBMPs.
AU  - Rifkin-Zybutz,R
AU  - Erridge,S
AU  - Holvey,C
AU  - Coomber,R
AU  - Gaffney,J
AU  - Lawn,W
AU  - Barros,D
AU  - Bhoskar,U
AU  - Mwimba,G
AU  - Praveen,K
AU  - Symeon,C
AU  - Sachdeva-Mohan,S
AU  - Rucker,JJ
AU  - Sodergren,MH
DO  - 10.1007/s00213-023-06399-3
EP  - 1745
PY  - 2023///
SN  - 0033-3158
SP  - 1735
TI  - Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: a cohort study from the UK Medical Cannabis Registry
T2  - Psychopharmacology
UR  - http://dx.doi.org/10.1007/s00213-023-06399-3
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:001007656000003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://link.springer.com/article/10.1007/s00213-023-06399-3
UR  - http://hdl.handle.net/10044/1/109950
VL  - 240
ER  -
Download